A recent systematic review and meta-analysis has established a significant correlation between pre-stroke frailty and adverse outcomes following reperfusion therapies for acute ischemic stroke (AIS). The analysis included data from 11 studies encompassing 194,699 participants, revealing a frailty prevalence of 37.2%. Notably, frailty was linked to a 2.19-fold increase in 90-day mortality and a 2.11-fold increase in one-year mortality, while showing no significant association with symptomatic intracranial hemorrhage or post-stroke disability.

These findings underscore the disease-modifying effects of frailty in the context of AIS, suggesting that frail patients may experience poorer survival outcomes post-treatment. The lack of association with symptomatic intracranial hemorrhage indicates that frailty’s impact may be more related to overall resilience and recovery rather than immediate procedural risks. This nuanced understanding of frailty’s role could inform clinical decision-making, particularly in selecting candidates for reperfusion therapies.

The implication for the field is clear: integrating pre-morbid frailty assessments into clinical practice could enhance patient stratification for AIS treatments, potentially optimizing outcomes. This study advocates for the necessity of large multi-centre prospective trials to further elucidate the relationship between frailty and treatment responses, paving the way for more personalized approaches in managing acute ischemic stroke.

Source: academic.oup.com